ANT308 TFA serves as an antagonist for the vasoactive intestinal peptide (VIP receptor). It significantly enhances the activation and proliferation of T cells. By inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin, ANT308 TFA impedes the migration and metastasis of melanoma cells and induces apoptosis. This compound is applicable in research related to acute myeloid leukemia (AML) and uveal melanoma (UVM).
Target-Kategorie:
Apoptosis|||PACAP
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
